Medpacto, Vactosertib designated as ‘orphan drug’ by FDA for pancreatic cancer Target the 4 trillion pancreatic cancer market' with Vactosert-5FU/LV/onivide combination therapy Medpacto (CEO Sungjin Kim) was designated as an Orphan Drug Designation (ODD) by the US FDA for the combination therapy of 'Vactosertib' and '5FU/LV/onivide' for the treatment of pancreatic cancer. Medpacto said, “Vactosertib and 5FU/LV/onivide combination therapy has already shown a high survival rate in preclinical studies, confirming its potential as a new treatment option for pancreatic c..........
